Article

Advice for Patients with Newly Diagnosed Glioblastoma

James Battiste, an oncologist with Stephenson Cancer Center in Oklahoma City, Okla., says patients with glioblastoma will likely have a lot of questions about the diagnosis.

James Battiste, an oncologist with Stephenson Cancer Center in Oklahoma City, Okla., says patients with glioblastoma will likely have a lot of questions about the diagnosis.

"First thing is don't be bashful about asking questions. Ask your oncologist as many things as possible," he says.

It is a difficult cancer to treat, but there have been advances, he says. Battiste encourages patients to seek out clinical trials and new information about the brain cancer because of the rapidly advancing field.

Related Videos
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Related Content